24 results about "Clostridium difficile (bacteria)" patented technology

The present application belongs to the technical field of bacterial detection, and particularly relates to a Clostridium difficile multi-locus genotyping detection kit and application thereof. The present application aims to provide a new method to directly type a main Clostridium difficile strain sequence type (ST). The technical scheme of the present application is a multiplex fluorescence PCR primer set and probe for Clostridium difficile multi-locus genotyping detection, wherein the primer and probe are shown in Seq ID No. 1-18. The present application discloses a multiplex fluorescence PCR reagent for 7 main ST types of Clostridium difficile based on a fluorescence PCR-dissolution curve method. The reagent can simultaneously detect 7 main ST types of Clostridium difficile in the same PCR reaction system.

The invention discloses a primer group for simultaneously detecting four equine digestive tract bacteria and application thereof, the primer group comprises primer sequences as shown in SEQ ID NO: 1-8, and the four equine digestive tract bacteria are salmonella enteritidis, salmonella typhimurium, clostridium difficile and lawsonia intracellular. Extracting total DNA (deoxyribonucleic acid) of a sample to be detected by using the excrement sample nucleic acid extraction kit; the total DNA is used as a template, and the primer group is used for multiple PCR reaction to obtain an amplification curve. According to the invention, a primer sequence with high sensitivity and specificity is adopted, so that the quality of a detection result is ensured; the detection method is simple to operate, time-saving and labor-saving; the detection flux is high, and the reagent consumable cost is low.

In one aspect, the invention relates to compounds useful as hybrid antibiotics, acting as both activators of the ClpP protease and inhibitors of RNA polymerase activity. Also disclosed are methods of using the disclosed compounds in the treatment of infectious diseases such as, for example, biofilm-mediated diseases and infectious diseases due to prosthetic joint infections, intracellular bacteria, and Gram-positive bacteria (e.g., Gram-positive bacteria selected from Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Clostridium difficile, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Corynebacterium diphtheria, Enterococcus faecalis, Enterococcus faecium, Listeria monocytogenes, Listeria ivanovii, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus hyicus, Staphylococcus intermedius, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present invention relates to the application of creatmycin in inhibiting gastrointestinal tract pathogenic bacteria, and the gastrointestinal tract pathogenic bacteria include but are not limited to: Helicobacter pylori, Clostridium difficile, Bacteroides fragilis, Escherichia fergusonii, Clostridium sporogenes.

The invention provides a non-protein metabolite of Thailand enterococcus d5B and application of the non-protein metabolite. The non-protein metabolite of the Thailand enterococcus d5B is a product obtained after enzymolysis of cell-free supernate of the Thailand enterococcus d5B by protease; the collection number of Thailand enterococcus d5B is CCTCC (China Center for Type Culture Collection) NO: M 20232279, and the Thailand enterococcus d5B is collected in the China Center for Type Culture Collection on November 20, 2023. The inventor discovers that the non-protein metabolite of the Thailand enterococcus d5B can play a role in killing clostridium difficile in a concentration-dependent manner, a good antibacterial effect can be achieved when the concentration of CFS containing the non-protein metabolite is 1 mu g / mu L or above, and the CFS containing the non-protein metabolite is an effective clostridium difficile bacteriostatic active component; the non-protein metabolite of the Thailand enterococcus has the antibacterial effect on the clostridium difficile for the first time at home and abroad, and has extremely high application value in the aspect of clinical treatment.

A method of manufacturing ostrich antibodies may include immunizing mature female ostriches with a mixture solution comprising Clostridium difficile toxin A and toxin B, obtaining eggs from the immunized ostriches, and purifying egg yolk antibodies from the eggs.

The invention belongs to the technical field of pathogenic bacterium detection, and particularly discloses a diluent for detecting clostridium difficile in an excrement sample and application of the diluent. The diluent for detecting the clostridium difficile in the excrement sample is prepared from fetal calf serum, bovine serum albumin, a detergent and an anti-interference agent according to a specific proportion. Wherein efficient extraction and detection of the clostridium difficile GDH are realized through broad-spectrum protection of the FBS, directional stabilization of the BSA, formation of a multi-layer protection network through the FBS-BSA, targeted splitting decomposition of the detergent and specific removal of the anti-interference agent. According to the invention, the relation among the splitting efficiency, enzyme protection and interference elimination is balanced by precisely regulating and controlling the proportion of the related components, and a reliable technical scheme is provided for clinical rapid diagnosis of clostridium difficile. The kit provided based on the diluent has the advantages of being good in stability, high in accuracy, low in cost, convenient to use and the like, and the clostridium difficile in an excrement sample can be efficiently and rapidly detected by adopting the kit.

The invention discloses a lactobacillus rhamnosus A21174 for inhibiting infection of multiple drug-resistant strains and clostridium difficile and application of the lactobacillus rhamnosus A21174. The lactobacillus rhamnosus A21174 has an obvious inhibiting effect on drug-resistant staphylococcus aureus, pseudomonas aeruginosa, drug-resistant escherichia coli, drug-resistant acinetobacter baumannii and clostridium difficile type strains. Compared with a commercial strain # imgabs0 # lactobacillus rhamnosus, the lactobacillus rhamnosus A21173 disclosed by the invention has a better antibacterial effect on clostridium difficile. The lactobacillus rhamnosus A21174 also shows good effects in in-vivo and in-vitro experiments such as artificial gastrointestinal fluid resistance, cholate resistance, aging resistance, life prolonging, oxidation resistance, cognition improvement and the like, so that the strain can be used as a probiotic agent for preparing a product for regulating intestinal flora, and has a good application prospect. The invention has important significance for preventing and / or treating diseases caused by multidrug-resistant bacterium infection, clostridium difficile and pseudomonas aeruginosa infection.

Bacterial infections evading the current antibiotic arsenal warrant new treatment options. The mainstay treatment for Clostridium difficile infections involves administration of the broad-spectrum antibiotic vancomycin, which also depletes the gut microbiome and its natural defenses. This leads to recurrent C. difficile infections in 20-30% of patients. Alternative treatment options are limited, triggering a perpetual cycle of relapse and recovery that may eventually lead to death. Keratinicyclin B represents a glycopeptide antibiotic chemotype with a mechanism of action that is selective for Clostridia. When combined, vancomycin (or other glycopeptide antibiotic) and keratinicyclin B interact synergistically to inhibit the growth of C. difficile at concentrations far lower than their respective minimal inhibitory concentrations. Such a combination therapy could allow for targeted colonization clearance at low antibiotic doses, thereby minimizing toxicity and reducing the likelihood of relapse.

The present invention relates to a bacterial strain of the species Fecalibacterium prausnitzii, which has been preserved in CNCM with a preservation number CNCM I-4573, and / or a culture supernatant thereof, for use in the treatment and / or prevention of a Clostridium difficile infection in an individual. The present invention also relates to a method for producing the bacterial strain of the species Fecalibacterium prausnitzii, and to a method for producing the bacterial strain of the species Fecalibacterium prausnitzii, which has been preserved in CNCM with a preservation number CNCM I-4573.

The invention provides a Bifidobacterium pseudocatenatum (Bifidobacterium pseudocatenatum) strain B24790 with the functions of inhibiting clinical multi-drug-resistant bacteria and resisting inflammation and application of the Bifidobacterium pseudocatenatum strain B24790, and belongs to the technical field of functional microorganisms. The invention discloses a bifidobacterium pseudocatenum strain B24790, and the preservation number of the bifidobacterium pseudocatenum strain B24790 is GDMCC No: 65515. The strain B24790 has good bacteriostatic activity on clinical multi-drug-resistant pathogenic bacteria such as clostridium difficile, acinetobacter baumannii HRAB-85, drug-resistant staphylococcus aureus, drug-resistant escherichia coli and pseudomonas aeruginosa PAO1, and also has a good anti-inflammatory effect. The strain B24790 is human-derived, has good gastrointestinal fluid resistance, and has the potential of colonization of human bodies. The bifidobacterium pseudocatenum strain B24790 provided by the invention has certain advantages in the aspects of drug-resistant bacterium infection and inflammatory diseases, can be used for preparing related products, and has a wide market prospect.

A bio-sensor device for the electrochemical detection of a bacterial pathogen, the device including a sample chamber and an electronic data module. The sample chamber includes passive sensing probes to detect pathogenic antigens in a sample containing the bacterial pathogen. The probes detect a reaction voltage corresponding to an antigen-antibody reaction occurring when the pathogenic antigens come into contact with an antibody specific for pathogenic antigens present in in the contents of the sample chamber and contacted by the electrical probes. The electronic data module detects and processes electrical signals detected by the conductive electrical probes corresponding to an amount of the antigen present in the sample, wherein the reaction voltage is detected at the time of the reaction.

The invention relates to the technical field of clostridium difficile anti-pollution treatment, in particular to a clostridium difficile specimen anti-pollution treatment device which comprises an inoculation assembly, the top of a base of the inoculation assembly is connected with a conveying belt, and a plurality of detachable culture dishes can be placed on the conveying belt. A first supporting rod on the base is rotationally connected with a disc which fixes a bacterial liquid box through a connecting rod. And a sliding rod on the inner side of the limiting block is connected with a U-shaped fork and is in sliding fit with the circular column. The double-end driving piece is installed on the second supporting rod, an output shaft of the double-end driving piece is connected with the first L-shaped rod and the second L-shaped rod, and the first L-shaped rod is in running fit with the U-shaped fork. The second L-shaped rod is provided with an air exchange assembly which can exchange air above the culture dish. A liquid dropping assembly and a coating assembly are arranged on a circular column on the connecting rod, so that bacterium liquid dropping and coating operation can be completed. According to the clostridium difficile specimen anti-pollution treatment device, efficient inoculation and coating of clostridium difficile specimens can be achieved, the pollution risk is effectively reduced, and the detection accuracy is improved.

The invention discloses a bacterial strain for preventing and treating diarrhea caused by clostridium difficile infection and application of the bacterial strain. The bacterial strain is saccharomyces boulardii HS5 and is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC NO.31317. The invention further discloses a preparation method of the bacterial strain for preventing and treating diarrhea caused by clostridium difficile infection and application of the bacterial strain for preventing and treating diarrhea caused by clostridium difficile infection. The preservation time is October 11, 2021; the bacterial strain for preventing and treating diarrhea caused by clostridium difficile infection is obtained through screening, the bacterial strain can remarkably inhibit growth of clostridium difficile, has excellent antibacterial performance on clostridium difficile, can further prevent and improve diarrhea symptoms caused by clostridium difficile infection, and is quick in effect and remarkable in effect.

The inventors of the present disclosure have undergone in-depth studies and found that an antibody that binds to and inhibits the proliferation of intestinal bacteria, particularly clostridium difficile cells and other intestinal bacteria cells. The present disclosure exerts the effect of providing antibodies and antigen-binding fragments thereof that bind to enteral bacteria, in particular, clostridium difficile and other enteral bacteria, and uses thereof.

The present disclosure relates to a mixture of HMOs with at least 85 wt% of LNFP-I, 2'FL and 3'SL of the total amount of HMOs in the mixture and the use of such a mixture to decrease Clostridium difficile and its toxins in a subject. Furthermore, the mixture of HMOs can increase microbial taxa that are diminished with aging in a mammal, including increasing Bifidobacteria such Bifidobacterium longum and / or Bifidobacterium adolescentis and Faecalibacterium such as Faecalibacterium prausnitzii in the gut of a subject, in particular an elderly.

The present invention provides an allocholic acid derivative having antibacterial activity and a pharmaceutical composition thereof, belonging to the field of medical technology. The allocholic acid derivative is a compound represented by formula (I), or a stereoisomer thereof, or a salt thereof, or a solvate thereof, or a prodrug thereof, or a metabolite thereof. This type of compound can effectively inhibit the growth of Clostridium difficile bacteria, has significant antibacterial activity, and has very good application prospects in the preparation of drugs for preventing and / or treating Clostridium difficile infectious diseases, recurrence of Clostridium difficile infectious diseases, or complications of Clostridium difficile infectious diseases.

The present invention relates to a composition comprising a monoclonal antibody binding to Clostridium difficile (C. difficile) for inhibiting a growth of Clostridium difficile (C. difficile), and a use thereof. In addition, the present invention discloses the composition for treating an inflammatory bowel disease, and a use thereof.

The invention provides Escherichia coli YC49 and application of the Escherichia coli YC49 in inhibiting clostridium difficile in cooperation with bacteroides, and belongs to the technical field of microorganisms. The invention provides Escherichia coli YC49, and the preservation number of the Escherichia coli YC49 is CGMCC (China General Microbiological Culture Collection Center) No. 34488. The invention also provides an effect of the Escherichia coli YC49 and bacteroides on synergistically inhibiting clostridium difficile, and further provides a compound probiotic composition, an in-vitro antibacterial product and a coprophilous fungus transplantation product. The Escherichia coli YC49 can accelerate the whole process from growth to decline of clostridium difficile, and a culture solution obtained after the Escherichia coli YC49 is combined with common bacteroides or the Escherichia coli YC49 and the common bacteroides are co-cultured can remarkably inhibit growth of early-stage clostridium difficile, so that the Escherichia coli YC49 has application significance in treatment of clostridium difficile infection.

The invention discloses a lactobacillus reuteri and a preparation method and application of a microbial inoculum of the lactobacillus reuteri, the lactobacillus reuteri subsp.reuteri OH114 is preserved in Guangdong Province Microbial Culture Collection Center (GDMCC), the preservation address is No.59 building, No.100 courtyard, Xianlie Middle Road, Guangzhou, the preservation number is GDMCC No.66528, and the preservation time is June 16, 2025. The lactobacillus reuteri newly researched and developed by the invention can effectively inhibit the growth of a plurality of enteropathogenic bacteria such as staphylococcus aureus, escherichia coli, salmonella typhimurium, clostridium difficile, clostridium perfringens, klebsiella pneumoniae, pseudomonas aeruginosa and candida albicans, regulate the balance of intestinal flora, prevent and treat adult diarrhea, and prevent and treat diarrhea. The invention provides a new scheme and way for preventing and treating infectious diarrhea, antibiotic-related diarrhea or irritable bowel syndrome diarrhea.

This document describes compositions, methods, and kits for detecting diarrheal pathogens from patient, food, or environmental samples. One embodiment described herein is primer pairs and probes for a multiplex polymerase chain reaction (PCR)-based assay for detecting gastrointestinal pathogens such as adenovirus, astrovirus, rotavirus, norovirus, zaruzin virus, Campylobacter species, Clostridium difficile, enteroaggregative Escherichia coli (EAEC), enteropathogenic Escherichia coli (EPEC), enterotoxin-producing Escherichia coli (ETEC), Shigella-like toxin-producing Escherichia coli (STEC), Shigella spp. / enteroinvasive Escherichia coli (EIEC), Escherichia coli O157, Listeria monocytogenes, Shigella-like bacteria, Salmonella spp., Yersinia enterocolitica, Vibrio species, Cryptosporidium species, Cyclospora kayanoides, Entamoeba histolytica, Giardia lamblia, or Giardia lamblia. Other embodiments include methods and kits for detecting gastrointestinal pathogens.

The application discloses a lactobacillus rhamnosus A21174 for inhibiting infection of multi-drug resistant strains and clostridium difficile, and application thereof. The lactobacillus rhamnosus A21174 has obvious inhibiting effect on drug-resistant staphylococcus aureus, pseudomonas aeruginosa, drug-resistant escherichia coli, drug-resistant acinetobacter baumannii and a model strain of clostridium difficile. Compared with a commercial strain of lactobacillus rhamnosus, the lactobacillus rhamnosus A21174 has better bacteriostatic effect on clostridium difficile. The lactobacillus rhamnosus A21174 also shows good effect in in-vivo and in-vitro experiments such as resistance to artificial gastric and intestinal fluid, resistance to bile salt, anti-aging, anti-oxidation, improvement of cognition and the like, and therefore, the strain can be used as a probiotic agent to prepare a product for regulating intestinal flora, and has important significance for preventing and / or treating diseases caused by infection of multi-drug resistant bacteria, clostridium difficile and pseudomonas aeruginosa.

Nosocomial infections are a major threat to the health sector. A specific category of these are the infections caused by antibiotic induced susceptibility to various pathogenic bacteria. This disclosure relates generally to method and system for combating infections due to antibiotic induced pathogens. The system provides strategies to combat pathogenic infections caused by multi-drug resistant (MDR) and extensively drug resistant (XDR) strains of antibiotic induced pathogens. The idea used in this disclosure utilizes the fact that multiple occurrences of a conserved stretch of nucleotide sequence on a pathogen genome and surrounded by genes encoding virulence factors or which are in vicinity of genes essential for survival of the candidate pathogen can be targeted to disrupt the overall genetic machinery of the pathogen. The present disclosure has been explained on sequenced genomes of Clostridium difficile and vancomycin-resistant Enterococcus sp.

The invention relates to the field of microorganisms, and discloses a microbial agent for inhibiting growth of clostridium difficile and enterococcus faecalis and application of the microbial agent. The microbial agent is prepared from bifidobacterium longum, lactobacillus delbrueckii subsp. Bulgaricus, bifidobacterium breve, lactobacillus reuteri, ackermann mucilaginosus and bacteroides ovatus. The six strains in the microbial inoculum cooperate to form a thick and dense symbiotic biological membrane, the thick and dense symbiotic biological membrane is rapidly planted in a symbiotic system of clostridium difficile (CD) and enterococcus faecalis (EF), a physical barrier is constructed, and colonization and diffusion of the clostridium difficile (CD) and the enterococcus faecalis (EF) are spatially inhibited; meanwhile, the content of leucine and ornithine secreted by EF in a system is remarkably reduced through metabolism synergy, cross-breeding of the leucine and the ornithine is blocked, growth is inhibited, CD spore germination can be inhibited by 100%, CD toxin secretion is reduced, the yield of pathogenic symbiotic biological membranes is reduced, CD pathogenicity is weakened in multiple links, all-around intervention on co-infection of CD and EF is achieved, and the application prospect is wide. And an efficient and safe solution is provided for the clinical problem.